Commentary
Volume 12:03, 2023

Journal of Hypertension: Open Access

ISSN: 2167-1095 Open Access

Unveiling the Role of PKAc Mutants in Adrenal Cushing's syndrome

Pérez López*

Department of Biochemistry and Systems Biology, University of Liverpool, Liverpool L69 7ZB, UK

Description

Adrenal Cushing's syndrome is a rare but debilitating condition caused by the excessive production of stress hormones, particularly cortisol, by the adrenal glands. In recent years, significant advancements in molecular research have shed light on the role of protein kinase A catalytic subunit mutants in the pathogenesis of adrenal Cushing's syndrome. Mutations in the PKAc gene have been identified in a subset of patients with this syndrome, leading to a dysregulation of cellular signaling pathways. One key aspect of PKAc mutants is their chronic mislocalization, which disrupts essential regulatory mechanisms and contributes to stress hormone overproduction. This article explores the intriguing link between PKAc mutants and their mislocalization in adrenal Cushing's syndrome and the implications of this phenomenon in understanding the disease's underlying mechanisms [1].

Protein kinase A is an essential cellular signaling enzyme that regulates a wide range of physiological processes. PKA consists of two regulatory subunits and two catalytic subunits forming a holoenzyme. Under normal conditions, PKA is tethered to A-kinase anchoring proteins at specific cellular locations, ensuring precise spatiotemporal control over its activity. However, in adrenal Cushing's syndrome, genetic mutations in the PKAc gene lead to the formation of PKAc mutants. These mutants are characterized by their chronic mislocalization, failing to remain anchored to AKAPs and resulting in uncontrolled activation. AKAPs play a crucial role in regulating PKA activity by providing a scaffolding platform for the holoenzyme, thereby ensuring localized and precise signaling.

The mislocalization of PKAc mutants disrupts this finely tuned regulatory mechanism. As a consequence, the abnormal PKAc mutants are no longer restricted to their designated cellular compartments, leading to uncontrolled activation and hyperactivity of PKA. In the context of adrenal Cushing's syndrome, this chronic mislocalization has a profound impact on the adrenal glands. PKAc mutants cause dysregulated activation of various signaling pathways involved in the synthesis and secretion of stress hormones, most notably cortisol. The hyperactivated PKA pathway stimulates the overproduction of cortisol in the adrenal glands, contributing to the characteristic symptoms and manifestations of Cushing's syndrome. To further investigate the role of PKAc mutants in adrenal Cushing's syndrome, researchers have developed a PKAc-W196R knockin mouse model [2].

This mouse model harbors a specific PKAc mutation analogous to one found in human patients with adrenal Cushing's syndrome. Interestingly, the PKAc-W196R knockin mouse recapitulates the hallmarks of adrenal Cushing's syndrome, demonstrating the significance of PKAc mutants in driving the disease phenotype. Studies have also revealed that different PKAc mutants found in adrenal Cushing's syndrome can lead to the activation of distinct downstream signaling pathways. For instance, the PKAc-W196R mutant has been shown to preferentially activate certain signaling molecules, contributing to cortisol overproduction. Conversely, the PKAc-L205R mutant exhibits a different signaling profile, highlighting the complexity of PKA dysregulation in this syndrome.

The discovery of PKAc mutants and their chronic mislocalization represents a significant advancement in our understanding of adrenal Cushing's syndrome. These mutants disrupt the tightly controlled regulation of PKA activity, leading to uncontrolled signaling and stress hormone overproduction. By investigating the mechanisms underlying PKAc mutants and their impact on cellular signaling, researchers can gain valuable insights into the pathogenesis of adrenal Cushing's syndrome. The development of animal models, such as the PKAc-W196R knockin mouse, further strengthens our ability to study and dissect the disease's molecular intricacies. Understanding the role of PKAc mutants and their mislocalization opens up new avenues for potential therapeutic strategies that target this dysregulated signaling, paving the way for more effective treatments for adrenal Cushing's syndrome [3].

Adrenal Cushing's syndrome is a rare and complex disorder characterized by the excessive production of stress hormones, particularly cortisol, by the adrenal glands. This condition can result from genetic mutations in the protein kinase A catalytic subunit gene, leading to dysregulated signaling pathways that drive the overproduction of cortisol. Recent advancements in molecular research have introduced a powerful tool for studying the pathogenesis of adrenal Cushing's syndrome the PKAc-W196R knockin mouse model. This unique mouse model harbors a specific PKAc mutation analogous to those found in human patients with adrenal Cushing's syndrome. By recapitulating key hallmarks of the disease, this mouse model offers invaluable insights into the underlying mechanisms of adrenal Cushing's syndrome and provides a platform for exploring potential therapeutic interventions.

The PKAc-W196R knockin mouse is a genetically engineered mouse that carries a specific mutation in the PKAc gene, mimicking a mutation identified in human patients with adrenal Cushing's syndrome. This targeted modification leads to the substitution of an amino acid at position 196 of the PKAc protein. Remarkably, this seemingly small change has profound effects on the activity and function of PKA, contributing to the development of adrenal Cushing's syndrome-like features in the mouse. The PKAc-W196R knockin mouse has been found to faithfully recapitulate key hallmarks of adrenal Cushing's syndrome. Notably, these mice exhibit excessive cortisol production in the adrenal glands, mirroring the hormone overproduction seen in human patients with the syndrome. Moreover, the PKAc-W196R knockin mice also display characteristic changes in adrenal gland morphology and function, consistent with adrenal Cushing's syndrome [4].

Interestingly, the PKAc-W196R mutation drives distinct downstream signaling pathways compared to other PKAc mutants associated with adrenal Cushing's syndrome. In addition to the PKAc-W196R mutant, another PKAc mutation, PKAc-L205R, has also been identified in some cases of adrenal Cushing's syndrome. Both mutants are associated with hyperactivation of the PKA pathway, contributing to cortisol overproduction. However, they appear to activate distinct downstream signaling pathways, leading to variations in the overall disease phenotype. The PKAc-W196R knockin mouse model has proven to be a valuable resource for understanding the molecular mechanisms underlying adrenal Cushing's syndrome. By precisely replicating key disease

***Address for Correspondence:** Pérez López, Department of Biochemistry and Systems Biology, University of Liverpool, Liverpool L69 7ZB, UK, E-mail: perezlopez@gmail.com*

Received: 29 May, 2023, Manuscript No. jhoa-23-107039; **Editor assigned:** 01 June, 2023, PreQC No. P-107039; **Reviewed:** 17 June, 2023, QC No. Q-107039; **Revised:** 22 June, 2023, Manuscript No. R-107039; **Published:** 29 June, 2023, DOI: 10.37421/2167-1095.2023.12.401

hallmarks, this model allows researchers to explore the consequences of PKAc mutations and their impact on adrenal gland function.

The distinct downstream signaling pathways driven by PKAc-W196R and PKAc-L205R mutants further highlight the heterogeneity of this condition, underscoring the complexity of adrenal Cushing's syndrome. The PKAc-W196R knockin mouse model opens up exciting possibilities for investigating potential therapeutic interventions for adrenal Cushing's syndrome. By studying the molecular pathways affected by PKAc mutations in this model, researchers can identify potential targets for drug development or gene therapy approaches. Understanding the specific signaling pathways associated with PKAc mutants may lead to the development of personalized treatment strategies that target the underlying molecular defects in individual patients [5].

Conclusion

The PKAc-W196R knockin mouse model is a groundbreaking advancement in the study of adrenal Cushing's syndrome. By recapitulating key hallmarks of the disease, this unique model provides researchers with a powerful tool to explore the molecular mechanisms driving cortisol overproduction in the adrenal glands. The discovery of distinct downstream signaling pathways driven by PKAc mutants, such as PKAc-W196R and PKAc-L205R, adds another layer of complexity to our understanding of this complex condition. Ultimately, insights gained from this model may pave the way for novel therapeutic interventions that target the underlying molecular defects in adrenal Cushing's syndrome, offering hope for improved management and treatment outcomes for affected individuals.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Omar, Mitchell H., Dominic P. Byrne, Kiana N. Jones and Tyler M. Lakey, et al. "Mislocalization of protein kinase A drives pathology in Cushing's syndrome." *Cell Rep* 40 (2022).
2. Omar, Mitchell H., Maryanne Kihiu, Dominic P. Byrne and Kyung-Soon Lee, et al. "Classification of Cushing's syndrome PKAc mutants based upon their ability to bind PKI." *Biochem J* 480 (2023): 875-890.
3. Groussin, Lionel, Eric Jullian, Karine Perlemoine and Albert Louvel, et al. "Mutations of the PRKAR1A gene in Cushing's syndrome due to sporadic primary pigmented nodular adrenocortical disease." *J Clin Endocrinol Metab* 87 (2002): 4324-4329.
4. Karl, Michael, S. W. Lamberts, Jan W. Koper and David A. Katz, et al. "Cushing's disease preceded by generalized glucocorticoid resistance: Clinical consequences of a novel, dominant-negative glucocorticoid receptor mutation." Variability in Glucocorticoid Sensitivity (1996): 133.
5. Drougat, Ludivine, Nikolaos Settas, Cristina L. Ronchi and Kerstin Bathon, et al. "Genomic and sequence variants of protein kinase A regulatory subunit type 1β (PRKAR1B) in patients with adrenocortical disease and Cushing syndrome." *Genet Med* 23 (2021): 174-182.

How to cite this article: López, Pérez. "Unveiling the Role of PKAc Mutants in Adrenal Cushing's syndrome." *J Hypertens* 12 (2023): 401.